CVRdatabase
Menu

GlyProVac ApS

Private limited companyCVR 39724758Odense SØActive

GlyProVac ApS is a private limited company, based in Odense SØ, active in manufacture of pharmaceutical preparations, founded in 2018. Equity was negative at the end of 2025 (−DKK 832k). The company made a loss in both 2024 and 2025, most recently DKK 5.2m. 6 people are registered in the company's management and ownership.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 2.1m−268.7% vs. 2024
Net profit−DKK 5.2m−71.4% vs. 2024
Equity−DKK 832k−27.2% vs. 2024
Employees3latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 3m to DKK 5.2m (2024 → 2025).

Employees

  • 6 fewer employees than a year earlier: 3 (07/2026) against 9 (07/2025).

Management and owners, last 24 months

  • New in management: Ann Zahle Andersen (chair of the board, 11/06/2026).
  • Stepped down: Ann Zahle Andersen (board member, 10/06/2026) and Tommi Petteri Kainu (chair of the board, 19/05/2026).
  • New owners registered: Bente Kristiansen (01/05/2026).
  • No longer registered as owner: Niels Hermann Kristiansen (01/05/2026).

Registrations, last 24 months

  • 13/10/2025: Share capital changed from 152,800 DKK to 155,104 DKK
  • 09/07/2025: Share capital changed from 148,238 DKK to 152,800 DKK
  • 20/11/2024: Share capital changed from 136,854 DKK to 148,238 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 6m−DKK 4m−DKK 2mDKK 0DKK 2mDKK 4m202020212022202320242025
EquityNet profit
Financial figures for GlyProVac ApS
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit1,0519931,321−815−577−2,129−268.7%
Operating profit (EBIT)−821−731−860−3,119−3,483−5,902−69.4%
Profit before tax−908−926−1,066−3,396−3,862−6,262−62.1%
Net profit−699−487−633−2,872−3,015−5,169−71.4%
Total assets3,7139,52912,2325,5134,3914,634+5.5%
Equity6722,4354,977852−654−832−27.2%
Liabilities2,6966,5346,4274,6625,0445,466+8.4%
Cash and cash equivalents4012,9152,1038772,0202,435+20.5%
Average number of employees434–56+20%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 3m−DKK 2m−DKK 1mDKK 0DKK 1mDKK 2mDKK 3m202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 832k at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for GlyProVac ApS
Financial yearPeriodPublishedFigures forDocuments
202501/07/2024 – 30/06/202529/12/2025The companyPDF not statedXBRL
202401/07/2023 – 30/06/202419/12/2024The companyPDFXBRL
202301/07/2022 – 30/06/202306/10/2023The companyPDFXBRL
202201/07/2021 – 30/06/202208/11/2022The companyPDFXBRL
202101/07/2020 – 30/06/202130/11/2021The companyPDFXBRL
202001/07/2019 – 30/06/202003/11/2020The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
02468101208/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 2.1mNo. 41 of 57
Better than 29% of the companies in the industry
Equity−DKK 832kNo. 47 of 59
Better than 21% of the companies in the industry
Number of employees3No. 32 of 59
Better than 47% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,218of 69,742
Better than 1%
No. 66,827of 69,964
Better than 4%
Same industry and fewer than 20 employees37 companies in the comparison
No. 23of 36
Better than 37%
No. 28of 37
Better than 25%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,297of 33,588
Better than 1%
No. 31,688of 33,687
Better than 6%
All companies of type ApS66,508 companies in the comparison
No. 65,952of 66,379
Better than 1%
No. 63,327of 66,505
Better than 5%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. GlyProVac ApS−DKK 2.1m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. GlyProVac ApS−DKK 5.2m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. GlyProVac ApS−DKK 832k
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. GlyProVac ApS3
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • I/S Rødeledsvej5%
  • GlycoPharma Holding ApS33.33%
  • Rossi Finans ApS10%
  • Bente Kristiansen10%
GlyProVac ApS

Management

6 active registrations

Executive management

Executive management at GlyProVac ApS
NameRoleAppointed
Anders BoysenCEO03/07/2018
Ann Zahle AndersenDirector03/07/2018

Board of directors

Board of directors at GlyProVac ApS
NameRoleAppointed
Willem Adriaan de JonghBoard member29/08/2021
Allan RosetzskyBoard member01/03/2022
Kirsten WintherBoard member05/10/2023
Ann Zahle AndersenChair of the board11/06/2026
Founders
GlycoPharma Holding ApS
Former management (6)
Former management at GlyProVac ApS
NameRoleAppointedResigned
Peter SmedegaardChair of the board03/07/201825/01/2019
Anders BoysenBoard member03/07/201801/03/2022
Ann Zahle AndersenBoard member03/07/201810/06/2026
Kirsten WintherChair of the board29/01/201904/10/2023
Tommi Petteri KainuBoard member01/01/202204/10/2023
Tommi Petteri KainuChair of the board05/10/202319/05/2026

Signing rule: Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.

Address and production units

1 active production units

Rørhatten 4
5220 Odense SØ

Odense Municipality · Postcode 5220

Production units
Production unitAddressEmployeesP number
GlyProVac ApSRørhatten 4, Tornbjerg, 5220 Odense SØ41023796054

Purpose

Selskabets formål er udvikle, kommercialisere, fremstille og sælge bakterielle vacciner.

The purpose is quoted from the register in Danish.

Changes year by year

60 registered events
20265 changesmanagement 3 · ownership 2
  • Ann Zahle Andersen appointed chair of the board
  • Ann Zahle Andersen stepped down as board member
  • Tommi Petteri Kainu stepped down as chair of the board
  • Bente Kristiansen registered as owner (10%)
  • Niels Hermann Kristiansen is no longer registered as owner
20253 changesaccounts 1 · capital 2
  • Annual report for 2025 published
  • Share capital changed from 152,800 DKK to 155,104 DKK
  • Share capital changed from 148,238 DKK to 152,800 DKK
20242 changesaccounts 1 · capital 1
  • Annual report for 2024 published
  • Share capital changed from 136,854 DKK to 148,238 DKK
202315 changesownership 8 · accounts 1 · management 4 · capital 2
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Annual report for 2023 published
  • Kirsten Winther appointed board member
  • Tommi Petteri Kainu appointed chair of the board
  • Tommi Petteri Kainu stepped down as board member
  • Kirsten Winther stepped down as chair of the board
  • Share capital changed from 130,904 DKK to 136,854 DKK
  • Rossi Finans ApS registered as owner (10%)
  • Share capital changed from 118,240 DKK to 130,904 DKK
  • Uddannelses- og Forskningsstyrelsen registered as owner (10%)
  • Niels Hermann Kristiansen registered as owner (10%)
  • AR CONSULT ApS is no longer registered as owner
  • SYDDANSK INNOVATION ApS is no longer registered as owner
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Niels Hermann Kristiansen is no longer registered as owner
202214 changesaccounts 1 · capital 2 · ownership 8 · management 3
  • Annual report for 2022 published
  • Share capital changed from 109,225 DKK to 118,240 DKK
  • AR CONSULT ApS registered as owner (5%)
  • Marigold Innovation ApS is no longer registered as owner
  • Share capital changed from 90,145 DKK to 109,225 DKK
  • Allan Rosetzsky appointed board member
  • Anders Boysen stepped down as board member
  • Uddannelses- og Forskningsstyrelsen registered as owner (20%)
  • Niels Hermann Kristiansen registered as owner (5%)
  • I/S Rødeledsvej registered as owner (5%)
  • GlycoPharma Holding ApS registered as owner (33.33%)
  • GlycoPharma Holding ApS is no longer registered as owner
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Tommi Petteri Kainu appointed board member
20212 changesaccounts 1 · management 1
  • Annual report for 2021 published
  • Willem Adriaan de Jongh appointed board member
20209 changescapital 2 · ownership 6 · accounts 1
  • Share capital changed from 72,397 DKK to 90,145 DKK
  • GlycoPharma Holding ApS registered as owner (50%)
  • Uddannelses- og Forskningsstyrelsen registered as owner (25%)
  • SYDDANSK INNOVATION ApS registered as owner (5%)
  • Marigold Innovation ApS registered as owner (5%)
  • GlycoPharma Holding ApS is no longer registered as owner
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Annual report for 2020 published
  • Share capital changed from 68,655 DKK to 72,397 DKK
20192 changesmanagement 2
  • Kirsten Winther appointed chair of the board
  • Peter Smedegaard stepped down as chair of the board
20188 changesfounded 1 · management 5 · ownership 2
  • Registered as GlyProVac ApS
  • Anders Boysen appointed ceo
  • Anders Boysen appointed board member
  • Ann Zahle Andersen appointed board member
  • Peter Smedegaard appointed chair of the board
  • Ann Zahle Andersen appointed director
  • GlycoPharma Holding ApS registered as owner (66.67%)
  • Uddannelses- og Forskningsstyrelsen registered as owner (20%)

Related companies

Same industry in Odense

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction